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Abstract
Background: Eclampsia is the main cause of maternal death in Brazil. Magnesium sulfate is the drug of choice for
seizure prevention and control in the management of severe preeclampsia and eclampsia. Despite scientific evidence
demonstrating its effectiveness and safety, there have been delays in managing hypertensive disorders, including
timely access to magnesium sulfate. To conduct a general situational analysis on availability and use of magnesium
sulfate for severe preeclampsia and eclampsia in the public health system.
Method: A situational analysis was conducted with two components: a documental analysis on information available
at the official websites on the policy, regulation and availability of the medication, plus a cross sectional study with field
analysis and interviews with local managers of public obstetric health services in Campinas, in the southeast of Brazil.
We used the fishbone cause and effect diagram to organize study components. Interviews with managers were held
during field observations using specific questionnaires.
Results: There was no access to magnesium sulfate in primary care facilities, obstetric care was excluded from urgency
services and clinical protocols for professional guidance on the adequate use of magnesium sulfate were lacking in the
emergency mobile care service. Magnesium sulfate is currently only administered in referral maternity hospitals.
Conclusion: The lack of processes that promote the integration between urgency/emergency care and specialized
obstetric care possibly favors the untimely use of magnesium sulfate and contributes to the high maternal morbidity/
mortality rates.
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Background
According to the World Health Organization (WHO),
about 830 women worldwide die every day from
pregnancy-related or childbirth-related complications.
Virtually all deaths occur in under-resourced locations,
most commonly among adolescents under 15 years of age
and women living in rural areas in poor communities
[1, 2]. The risk of dying from maternal causes is 33
times higher in a low-income or middle-income country
than in a high-income country [2].
In a recent multicenter study conducted in Brazil, dur-
ing a one-year period, 82,388 hospitalized women were
monitored for any pregnancy-related complication in 27
referral maternity hospitals. Altogether these maternity
hospitals represented the five regions of the country.
Among the 9,555 women identified with severe maternal
complications, hypertensive disorders was the main
cause of hospital admission (73 %), and eclampsia was
the major cause of death in the country [3, 4].
Adequate management of obstetric complications at
different levels of women’s healthcare has been pointed
out as the main factor for improvement in maternal and
perinatal prognosis. It reinforces the concept that delay
during obstetric care is the determining factor for worse
outcome [5]. Currently, the drug of choice for seizure pre-
vention and control is magnesium sulfate and the delay in
using it can compromise effective obstetric care [6, 7].
In 1995, an international multicenter randomized con-
trolled trial, The Eclampsia Trial, compared magnesium
sulfate to the anticonvulsants diazepam and phenytoin.
Magnesium sulfate was considered the best medication
for the control and recurrence of eclamptic seizures.
Women were randomized to use diazepam or phenytoin
with magnesium sulfate. In both groups of women, mag-
nesium sulfate was capable of reducing seizure recur-
rence in 52 and 67 %, respectively [8]. Another trial with
the same characteristics, the Magpie Trial, evaluated
4.999 women with severe preeclampsia who were ran-
domized for medication use. Magnesium sulfate de-
creased eclampsia by more than 50 % and major adverse
events were rare, such as respiratory depression (0.9 %),
respiratory arrest (0.1 %) and need for calcium gluconate
(0.3 %) [9].
In a recent literature review, it was estimated that al-
tered patellar reflex, respiratory depression and calcium
gluconate requirement occurred in 1.6, 1.3 and 0.15 % of
cases, respectively, during use of magnesium sulfate in
9,556 women enrolled into the study [10]. Two other
studies also compared the safety of magnesium sulfate
with placebo or no other anticonvulsant. The first study
evaluated 11,444 women with preeclampsia and de-
scribed that major adverse effects such as the absence or
decrease in reflex reactivity and respiratory depression
were rare occurring in 1 % of women [11]. The second
study reviewed 143 publications on 10,795 women with
preeclampsia and found no association between medi-
cation use and maternal death, or cardiac/respiratory
arrest [12].
The drug has a very low toxicity, low cost and is simple
to use by trained physicians and nurses. Drug administra-
tion may be controlled by clinical signs (diuresis, respira-
tory rate and tendon reflexes), and serum magnesium
level measurements are not routinely needed. Toxicity is
easily identified and reversed by interrupting drug use or
administering the antidote, calcium gluconate [9]. Despite
evidence, however, its use is limited and justified by the
lack of availability, conditions of applicability, infrastruc-
ture and training for timely and proper drug use [13]. Sci-
entific uncertainties also contribute to its underutilization,
such as the mechanism of action of the antiepileptic drug,
minimum effective dose [14, 15] and level of care recom-
mended for disease management (primary, secondary and
tertiary). Nevertheless, its use may be implemented in pri-
mary healthcare units (PHU) [7, 16].
Magnesium sulfate, through the decades has contrib-
uted significantly to the reduction in maternal and peri-
natal morbidity and mortality due to preeclampsia and
eclampsia [7, 17]. There is however some clinical condi-
tions that could still benefit from a timely use of this drug,
with a general feeling that its potential impact on pre-
eclampsia and eclampsia is not enough explored. There-
fore, the purpose of this study was to conduct a general
situational analysis on availability and use of magnesium
sulfate for severe preeclampsia and eclampsia in the public
health system.
Methods
This was a study using a situational analysis approach
[18] focusing the use of magnesium sulfate in severe pre-
eclampsia and eclampsia in the public health system in
Brazil. This was performed using two strategies: first, a
documental analysis for identifying the available current
pertinent national policies and legislation, and second, a
cross sectional component exploring aspects on the use
of magnesium sulfate at all levels of the health system.
The situational analysis is known as a strategy to be im-
plemented to gather a general overview of the current
situation in a specific setting and with the purpose of
further implement actions for improvement. Theoretic-
ally it involves “to define the nature and extent of the
problem in the local context; to map the perceptions
and experiences of key stakeholders in relation to the
problem; to identify existing strategies and activities
which address the problem; to identify the actors and or-
ganizations that are already active in the area; to identify
the actors and organizations that could be important
partners; and to identify gaps in existing strategies and
activities” [18]. All these activities were judged to
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perfectly fit the needs for a comprehensive understand-
ing of the problem identified.
To understand all the processes required for the drug
use, we used the Fishbone or cause/effect diagram. This
diagram was conceived as a tool for quality control by
Kaoru Ishikawa in 1982. It was developed to identify the
root cause of the problem and process restrictions, con-
tributing to continuous quality improvement through col-
laborative team work. The structure of the diagram may
be classified according to the convergent reasons for the
problem (method, material, manual labor, machine, meas-
urement and environment). It is presented in a graphic
and synthesized manner for better visualization [19, 20].
We constructed a diagram with access to magnesium
sulfate as the problem, in an attempt to understand and
identify all processes involved ranging from public policies
to drug use. Other studies on preeclampsia/eclampsia have
already employed this method in the literature [21–23].
Four components were identified as integrating and in-
terrelated parts in this process, and they were classified as:
a. Regulatory and governmental component (legislation,
protocols, drug selection and registration); b. Drug com-
ponent (accessibility, availability and applicability of the
drug); c. Structural component of the healthcare network
(PHU, urgency care units (UC) /emergency room (ER)
and emergency mobile care service and referral ma-
ternities, according to the municipal organization); d.
Organizational component (unit managers) (Fig. 1).
There were three distinct steps for the development of
the method proposed: 1) documental analysis at three
governmental levels; 2) exploratory analysis composed of
field observation in women’s healthcare units; and 3)
interview with local unit managers at each setting of the
healthcare network (HCN).
For the first step, the documental analysis on regula-
tory/governmental legislation and public policies was
performed by searching Web pages to identify public
policies on women’s healthcare promoting strategic pro-
grammatic actions to reduce maternal mortality and
treat women with severe hypertensive disorders during
pregnancy and post-partum period. This search was per-
formed at the three correspondent government levels:
federal, state and municipal, considering that some dif-
ferences could exist among them taking into account
their relative autonomy [24]. Websites accessed were
from the Ministry of Health (MH), the São Paulo State
Department of Health (SDH) and the Campinas Munici-
pal Department of Health (MDH).
In the main webpage of the Ministry of Health, we
accessed the National Health System (SUS) legislations to
identify those providing information on the country’s health
system that were relevant to the study. We sought actions,
programs and strategies exploring rules of the Department
of Basic Care, Family Health Program, Primary Healthcare,
Stork Network and Urgency/Emergency Network.
Still as part of documental analysis, we found protocols
containing recommended treatment for severe hypertensive
disorders during pregnancy and postpartum period. We
searched for protocols in the Ministry of Health online li-
brary, as well as in the São Paulo State Department of
Health and the Campinas Municipal Department of Health.
For analysis of the regulatory component of the drug,
we checked its record and inclusion in the drug lists
(national, state and municipal). Its characteristics for
Fig. 1 Framework with the fishbone diagram to assess to magnesium sulfate use in severe preeclampsia and eclampsia. (Edraw Max software).
Structural component: EMCS (Emergency Mobile Care Service), Maternity, Emergency Room, Urgency Care, Primary Health Unit. Organizational
component: manager; Pharmaceutical component: accessibility, availability, applicability; Regulatory component: legislation, protocols, registration,
national drug list
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indication and prescription were taken into account,
following the National Sanitary Surveillance Agency
(ANVISA), the organ responsible for drug registration
and approval in the country.
The second and third steps were regarded exploratory
analysis from field observation in women’s healthcare
units and interview of managers. Assessment of availabil-
ity, accessibility and applicability of magnesium sulfate
was conducted by field observations and simultaneous in-
terviews with managers in PHU, UC, ER, EMCS and refer-
ral maternity hospitals. In order to avoid any courtesy bias
and to assure homogeneity, the visits were performed
without previous scheduling by only one interviewer who
is from the research team (FAL). Interviews used a ques-
tionnaire specifically built for the study applied from July
to December 2015. It contained information on availability
of technical protocols for management of the condition in
all health care levels, the flow of the woman in situations
of hypertensive urgency and emergency, equipment, hu-
man and material resources needed by the level of care.
For the structural component of the study a case study
was performed with the municipality of Campinas using
a cross sectional design. We selected a convenience sam-
ple from Campinas, including its whole health units at
all levels, the Health Care Network (HCN). It contains
63 PHC, 4 UC, 2 ER, the EMCS and 3 referral maternity
hospitals (Fig. 2) [25]. Campinas is the third largest city
in the State of São Paulo, in the southeastern region of
Brazil. It has 1.080.034 inhabitants and 504,175 women
[26]. The city is divided into five districts (north, south,
east, southeast and northwest) with around 200.000 in-
habitants in each one, which has also its district health-
care surveillance and referral hospital units according to
neighborhood and complexity.
The data collected were entered in Excel 2007 pro-
gram spreadsheets. Database was analyzed for logical
Fig. 2 Healthcare Network (Health facilities) of the municipality of Campinas, SP, Brazil. Arabic numerals: geographic locations of the PHU (primary
health unit);☆ : Maternity hospitals; ○: UC/ER (urgency care/emergency room). crossed out numbers: non-participating PHU
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consistency and any errors identified were corrected.
The absolute (n) and relative (%) frequencies of categor-
ical variables were calculated. To construct the diagram
with its layout, the “Edraw Max” software was used.
The study protocol was approved by the Institutional
Review Board (IRB) from the School of Medical Sciences
of the University of Campinas, by the Research Ethics
Committee of MDH and by the Clinical Directors of
maternity hospitals. A written free informed consent
term was used for managers and applied during the in-
terviews (IRB protocol number 658.325).
Results
Our results are presented according to the four compo-
nents of the fishbone diagram and are available in the
summary table (Table 1):
Regulatory/governmental component
This component corresponds to the documental analysis
as planned. In the Ministry of Health website on basic
legislation for the National Health System, it was pos-
sible to identify specific legislation on the reduction of
maternal mortality and management of hypertensive
Table 1 Magnesium sulfate in preeclampsia/eclampsia in public health system in the municipality of Campinas, SP - Brazil
Component Facilitator Barriers
Regulatory
Legislation ✓ Healthcare Pact of 2006 - administrative rule
n° 399/MH
✓ Application of MgSO4 is made only in hospitals
✓ Level for application of MgSO4 is not available
✓ Stork Network of 2011 – Administrative rule
n° 1459/ MH
✓ MgSO4 20 and 50 % is included in the basic and
essential list of drugs for hospital units
✓ Urgency/ Emergency Network - Administrative
rule n° 1600/ MH
✓ Prioritizes trauma, cardiovascular and cerebrovascular
care
Registration ✓ RENAME – MH and SDH-SP: has MgSO4, ✓ No specification for use in hypertensive syndromes
✓ Drug registration - ANVISA ✓ Municipal list: no reference to MgSO4
Protocol ✓ Urgency/emergency protocol /2000 - MH ✓ Municipal Protocol: lacking
✓ Level for application of MgSO4 is not available✓ High-risk pregnancy protocol /2012 – MH
✓ No specification for use in hypertensive disorders✓ SDH-SP protocol / PN and Puerperal Technical
Manual 2010
✓ Basic Life Support (BLS) and Advanced Life Support
(ALS) / MH
✓ EMCS municipal protocol /guidance of patient
transportation in cases of pregnancy-related hypertension
Drug
Conditions of applicability ✓ All ✓ PHU: only essential equipment
Availability ✓ Presence UC/ ER and Maternity Hospitals ✓ Lacking PHU and EMCS
Structure
Equipment ✓ Available at UC, EMCS and Maternity Hospitals ✓ PHU: only essential equipment
Physical ✓ Distribution apparently adequate for HCN
✓ PHU with medication room adapted to local
architecture
✓ UC, EMCS and Maternity Hospital with adequate
architecture
Organizational ✓ Presence of physicians ✓ PHU: destined to ambulatory scheduling
✓ Insufficient number of physicians for urgencies in PHU
✓ Exclusion of UC/ER in the care of pregnant women
✓ Protocol lacking in UC/ER, available in 56 % of PHU,
present in the maternity hospitals
✓ Exclusive use by the obstetrician
✓ Responsibility not established
✓ Elective work activity (programmed schedule)
✓ Lack of training
ANVISA National Sanitary Surveillance Agency, EMCS Emergency Mobile Care Service, ER emergency room, HCN Healthcare Network, MH Ministry of Health, PHU
primary health unit, PN prenatal care, RENAME National Drug List, SDH State Department of Health, UC urgent care
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disorders. Administrative rule GM number 399 of Feb-
ruary 22nd, 2006 initiated the Health Pact, restructuring
the health system in the country into primary healthcare
(PHC) and healthcare networks (HCN). It prioritized the
consolidation and qualification of Family Strategy as the
model of PHC for modelling the HCN [27]. One of its
goals is to reduce maternal mortality in the country, en-
suring “materials and medication for treatment of
Hypertensive Syndromes in childbirth”. The HCN orga-
nizes healthcare services into maternal healthcare, infant
healthcare, disability healthcare, urgent and emergency
care, among others [28].
The Stork Network, instituted within the scope of the
National Public Health System (SUS) under the adminis-
trative rule 1459 of June 24th, 2011, organizes maternal
healthcare. It determines the healthcare settings a
woman will follow in her itinerary. The aim of the Stork
Network is to ensure that the woman receives human-
ized care during pregnancy, childbirth and the postpar-
tum period. It is focused on childbirth care, offering a
guarantee of access, care and resolution [29]. All health-
care settings are equally relevant and distinguished by
technological density. PHC is responsible for the inter-
relationship and maintenance of these settings, organiz-
ing different tasks in different settings to overcome
system fragmentation [28].
To instruct regional and municipal actions on Stork
Network implementation, administrative rule 650 of
November 5th, 2011 technically regulates functioning
of obstetric and neonatal healthcare services [30]. In
this resolution, injectable magnesium sulfate at con-
centrations of 20 and 50 % is included in the basic
and essential list of drugs for hospital units [31].
Each healthcare setting shall fulfill specific aims in ur-
gent care. The primary health unit will be responsible
for initial medical care until patient referral to another
healthcare setting. The EMCS will render the care re-
quired during transportation. The UC unit is responsible
for the resolution and qualified care of acute clinical
cases. It delivers initial medical care in surgical cases or
trauma, stabilizing patients and performing early diagnos-
tic investigation, defining urgency destination and hospital
referral. However, the urgency/emergency network priori-
tizes cardiovascular and cerebrovascular care, trauma, and
does not include maternal care in this priority [32].
To assist pregnant women diagnosed with severe pre-
eclampsia and eclampsia, standardized clinical protocols
on the timely and proper use of magnesium sulfate are
required in a hospital and non-hospital setting. The
Ministry of Health has a protocol on Maternal Urgencies
and Emergencies [33] and a Technical Manual on High-
Risk Pregnancy [34], where there are guidelines for the
diagnosis and treatment of severe preeclampsia/eclamp-
sia and for the timely and proper use of magnesium
sulfate. The Sao Paulo State Department of Health also
has a Technical Manual of Prenatal and Puerperal Care
[35]. However, none of the protocols refers to the setting
where the medication should be applied.
The EMCS has two clinical protocols available: Basic
Life Support and Advanced Life Support. None of these
protocols contains recommendations for the use of mag-
nesium sulfate [36]. The EMCS Manual of Medical Rou-
tine of the MDH Campinas predicts transportation and
approach of the pregnant woman with severe hyperten-
sive disorders, although it does not specify the use of
magnesium sulfate [37].
Availability of magnesium sulfate was confirmed by
the drug registration in the National Sanitary Surveil-
lance Agency (ANVISA), in concentration of 10 and
50 % for parenteral use [38] and included in the National
Drug List (RENAME), without specifying its use in Ob-
stetrics [39]. At the website of the Sao Paulo State De-
partment of Health, we found the same medication list
as in the Ministry of Health (RENAME). The MDH of
Campinas has a standardized drug list to supply health-
care units that does not include magnesium sulfate in
any of its injectable presentations [40, 41].
Drug component
Access to medication is dependent on several processes,
starting at entry into the PHU and family healthcare
program. The municipality also has good access to pre-
natal and childbirth care; 12,573 or 78.7 % of pregnant
women had seven prenatal visits or more in 2014 and
99.6 % of deliveries in the metropolitan region of Campi-
nas occurred in hospitals [42, 43]. Quality assessment of
prenatal care according to risk identification, early diag-
nosis of preeclampsia/eclampsia and early treatment of
severe cases were not aims of this study. However, the
medication was not part of the PHU drug list and was
not available for that purpose. On the other hand, in our
field observation we also identified minimum conditions
for safe drug use (Table 2).
Structural component
In terms of health service structure, it was possible to
visualize three action groups and services institutionally
grouped under the National Health System: primary
care, formed by family strategy and PHU; medium- and
high-complexity care formed by outpatient facilities; and
hospital admissions in public maternity hospitals.
Each primary healthcare unit is responsible for the
care of approximately 20,000 inhabitants. Healthcare is
delivered by multiprofessional teams. Families are
enrolled and healthcare is provided by scheduled visits.
Along with primary health units, family healthcare
programs are aimed to expand and qualify basic care,
improving its resolution. Both units are part of the
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“Integral Urgency/Emergency Care Plan”. Attributions of
these units include patient reception and assessment of
the risk and complexity of acute urgent case arriving
spontaneously [44].
All PHU visited (n = 59/63) had a medication room
and nursing staff for management and surveillance
during working hours. In the medication room, gur-
neys, armchairs, IV lines, sphygmomanometers and
stethoscopes were identified, although not all settings
had the physical structure to care for urgent cases.
Some PHU had greater surveillance resources, with
devices such as pulse oximetry, cardiac monitor and
defibrillator in 34 (57.6 %), 8 (11.6 %) and 9 (15.9 %)
units, respectively. Clinical protocols were irregularly
available at various maternal care units (PHU 33/59;
UC + ER 0/5; EMCS 0/1; maternity 2/2). (Table 2).
UC and ER have the infrastructure, materials, equip-
ment and teams prepared for urgency/emergency care
due to the free demand of critical patients. These facil-
ities function on a 24-h basis and ensure clinical support
until patient transfer to a hospital. However, these units
have no obstetrician and/or neonatologist and/or specific
beds in its work structure.
EMCS has the resources for intensive care and ensures
adequate transportation of clinical, pediatric and obstet-
ric urgent cases to referral centers, in addition to all
other situations that require removal to a more complex
level of care.
Three maternity hospitals, two of them visited, ac-
count for urgency/emergency care in pregnancy, child-
birth and postpartum period, both with the structure to
use magnesium sulfate and deliver adequate maternal-
infant care. Healthcare is provided by the medical staff,
nursing staff, multidisciplinary teams and other support
medical specialties, in a 24-h daily.
Organizational component
During visits, it was possible to observe the presence of
physicians, nursing staff and multidisciplinary healthcare
team in the facilities. We were able to interview health-
care unit managers, inquiring about magnesium sulfate,
drug availability and maintenance, along with experience
in hypertensive pregnancy-related urgency.
Reports of all PHU managers, i.e. 100 % visited, reiter-
ated that the physical structure and technical resources
were limited for magnesium sulfate administration. In
addition, they did not participate in the choice of drugs
standardized by the MDH, according to complexity of
care. In these units, managers questioned which profes-
sional would be apt for drug use, since it was known that
“the drug was exclusively used by obstetricians and gy-
necologists in a hospital setting”. Difficulties in receiving
the urgent case were also reported, since work is per-
formed according to a programmed schedule. The num-
ber of physicians is inadequate to care for this demand
without interruption of elective care. Time is restricted
for case management, since the unit is not open full-
time. Nevertheless, there was a high demand for proper
training in magnesium sulfate use in preeclampsia and
eclampsia.
In the UC and ER settings, it could be observed that
technical conditions and infrastructure permit the
provision of more complex care. However, local man-
agers reported that these units have no access to preg-
nant women, since they are instructed to seek maternity
hospitals in case of urgency and emergency. The reason
is that there is no obstetrician and/or medical team
available for patient care.
In the EMCS, the manager reported that the health-
care team was prepared and motivated for the use of
magnesium sulfate in preeclampsia and eclampsia. It
Table 2 Available resources for management of magnesium sulfate at health facilities from the Healthcare Network in Campinas, SP, Brazil
Field Observation PHU UC + ER EMCS MATERNITY
n (59) % n (5) % n (1) % n (2) %
Protocol for SPE/E Diagnosis and Treatment 33 56 0 0 0 0 2 100
Minimum conditions for intravenous usea 59 100 5 100 1 100 2 100
MgSO4, 10 % vials 0 0 5 100 0 0 2 100
MgSO4, 50 % vials 0 0 0 0 0 0 2 100
Calcium gluconate, 10 % vials 52 88 5 100 1 100 2 100
Cardiac monitor 8 14 5 100 1 100 2 100
Pulse oximetry 34 58 5 100 1 100 2 100
Cardiac defibrillator 9 15 5 100 1 100 2 100
Laryngoscope 57 97 5 100 1 100 2 100
Orotracheal cannula 59 100 5 100 1 100 2 100
EMCS Emergency Mobile Care Service, ER emergency room, PHU primary health unit, UC urgent care
aMinimal conditions for intravenous MgS04 use: syringe, needle, tubing line, fluid, adhesive tape and cotton
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was believed that these practitioners could contribute to
improved maternal clinical conditions during more pro-
longed transportations. Maternity managers described
that clinical conditions of the transferred women could
have been better, if magnesium sulfate had been admin-
istered during the entire healthcare period until patient
referral. Their report confirms the statement made by
the EMCS manager.
Discussion
Analyzing the components of the fishbone diagram, our
study identified barriers to the timely proper use of mag-
nesium sulfate for severe preeclampsia in the national
public health system (SUS) in the city of Campinas.
Magnesium sulfate registration for use in the country,
its selection in the national drug list, the presence of
specific protocols, and maternal healthcare in the muni-
cipality of Campinas with many PHU strategically dis-
tributed, according to regional population density, would
allow the reception and management of preeclampsia
and eclampsia, complying with legislation and working
SUS guidelines. However, in the daily unit routine, many
barriers still need to be overcome.
Government understanding that preeclampsia and
eclampsia are public health issues with participation
in maternal death, guides legislative strategies towards
dealing with the problem. Regulatory national policies
(primary healthcare, the Stork network and urgency/
emergency care) include maternal hypertensive urgency
care. However, these policies are not interlinked and artic-
ulated to ensure integrated and continuous maternal
healthcare. A clear example of this inadequacy is the offi-
cial recognition that magnesium sulfate is only obligatory
in hospital settings, with potential loss of opportunities do
timely and proper management of severe clinical situa-
tions. Studies have already demonstrated the use of mag-
nesium sulfate in primary health care could reduce the
recurrence of eclampsia by 78 % [14].
These governmental policies should be offered to mu-
nicipalities by the Ministry of Health. However, man-
agers have responsibility to decide whether the actions
proposed will be developed or not in the municipality.
Choosing not to participate in these policies may nega-
tively influence the quality of care, contributing to in-
creased sequelae and death during pregnancy and
postpartum period [45].
Clinical protocols are quality tools in healthcare that
point towards diagnosis and treatment. Guidelines, ac-
tions and resources necessary for a certain purpose are
established. The elaboration of these tools connects le-
gislation and scientific evidence to clinical practice. It
ensures a safe source of knowledge of the timely and
proper use of magnesium sulfate in severe preeclampsia
and eclampsia. Nevertheless, to contribute to timely
drug use, protocols need to be systematically present in
the workplace for consultation. Strategies to understand
and learn the protocol, in addition to the working
organization proposed by the HCN, should be part of
SUS organizational structure to construct and/or recycle
knowledge of health professionals in a close, constant
and effective manner [46]. Overseeing the health profes-
sional for capacitation and optimal working conditions,
contributes to the good quality of the service, processes,
results, strengthening relationship with the work unit
[47]. In fact, the results of the current study showed
that not all PHU, urgency and emergency services
and mobile services have guidelines easily available
for consultation, nor a systematic regular training
program of personnel for using magnesium sulfate
was implemented.
Our results indicated that the PHU in Campinas in its
working organization understands that it is not eligible
for urgent or emergency care. It recommends that preg-
nant women seek referral maternity hospitals in critical
situations. This limits its action and compromises the
level of care. Its limited technical resources and insuffi-
cient number of healthcare workers to care for urgent
cases reinforces this understanding and negatively affects
the capacity of health professionals to provide high-
quality healthcare.
In an emergency situation, the pregnant woman is
instructed to seek a maternity hospital for first medical
care. Rapport is lost and the opportunity to evaluate the
required complexity is missed. The pregnant woman is
responsible for her transportation, often depriving her of
the high-quality EMCS transport, in addition to an ad-
equate and timely management of preeclampsia/eclamp-
sia. On the other hand, unnecessary patient removal to a
referral hospital unit increases costs and overburdens ER
in maternity hospitals. The healthcare specialist is dislo-
cated from assisting severe cases to care for cases of low
complexity and simple resolution. This organizational
healthcare practice may delay the proper use of mag-
nesium sulfate, deteriorating maternal and perinatal
prognosis [48].
A lack of adequate and timely transportation, lack
of initiative to seek help or recognize alert signs for
the diagnosis, and adequate care in the referral hos-
pital unit are the three main causes of delays associ-
ated with maternal death. Strategies to reduce delay
may contribute to decreased morbidity and mortality
rates [5]. A recent systematic review identified a delay
rate of 92.3, 82.1, and 63 % in the transportation, in
the capacity to recognize alert signs, and in offering a
quality of care, respectively, associated with a severe
maternal outcome [48].
EMCS in the municipal healthcare organization
plays a vital role in the management of maternal
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urgencies. Its healthcare workers are responsible for
the safe transportation and management of maternal
emergency cases. Nevertheless, the occurrence of
severe preeclampsia and eclampsia is rare and wide-
spread, providing little experience to EMCS health-
care workers. Since magnesium sulfate is not available
for this specific treatment, proper drug use is delayed
until the patient arrives at the hospital and care is
provided by obstetricians and ICU professionals. Ex-
perience in proper use of the medication is delegated
only to these healthcare professionals.
The need to organize and coordinate health care
services at various levels of technological density, eco-
nomic restrictions and containment of expenditure
led Brazil, as well as countries from the European
Union, to amplify the functions of primary healthcare.
Its actions have been qualified, strengthened and ex-
panded. This seems to be the pathway to humanized,
problem-solving oriented care, committed to the ra-
tional use of resources [49]. However, the PHU will
remain underused, as long as the municipality recom-
mends that pregnant women should seek care in ma-
ternity hospitals in urgent situations, and as long as
the reception of urgencies in these units is negatively
perceived by pregnant women and their relatives [50].
Even with qualification and strengthening of pri-
mary healthcare, and capacitation of practitioners in
the use of magnesium sulfate in severe preeclampsia
and eclampsia, access to medication demands a com-
plex construction. The drug should be available in
healthcare units and prescribed by a medical practi-
tioner, administered either by the physician who or-
dered the drug or by another professional. It should
be dependent on resources for drug administration
before benefitting the pregnant woman. Operationali-
zation of this process passes through various actors.
These actors are required to know the reality of ma-
ternal hypertension in our country. Furthermore,
these actors need to be persuaded and involved in the
conduction and timely and proper use of the drug.
Lack of drug availability, structural and technical re-
sources, in addition to skilled health professionals
who are committed are issues that are also shared by
other countries dealing with the problem [21–23].
Our study had some limitations. Data were collected
at a specific time and barriers and facilitators could vary
over time at each unit visited. Lack of access to medica-
tion in the PHU were barriers only mentioned by local
managers and not by pregnant women or other health
professionals at each unit visited, even if they were
inserted in the local SUS context. Only two out of three
maternities responsible for maternal care could be vis-
ited. The study was conducted in only one municipality
of the southeastern region of Brazil. However, the
regulatory and drug components identified in this study,
are defined for the whole country.
Furthermore, considering data from a national study,
the prevalence of eclampsia was about four times higher
in the North, Northeast and Center West regions com-
pared to the South and Southeast regions [4], thus it
could be extrapolated in a systematic and timely manner
that lack of access to magnesium sulfate is even higher
in other regions in Brazil.
The fishbone diagram is a tool that was helpful in
identifying barriers for the use of magnesium sulfate in
severe preeclampsia and eclampsia. It allowed the study
to point out the multifactorial challenges to effectively
achieve the provision of high-quality care in hyperten-
sive emergencies during pregnancy.
Conclusions
Interventions such as the inclusion of magnesium sul-
fate in the national drug list, starting drug use in the
PHU, specifying that it is the drug of choice for treat-
ment of severe preeclampsia and eclampsia with spe-
cific protocols and simplified leaflets for medication
use are required. In addition, refreshing courses and
continuous professional training, restructuring the
PHU to ensure the supply, distribution and applicabil-
ity of the medication at all levels of maternal care
may contribute to improved rates of maternal and
perinatal morbidity and mortality.
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